Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Three GOP Senators Say They Will Vote Against Sotomayor Confirmation
Senate Judiciary Committee ranking member Jeff Sessions (R-Ala.) -- along with committee members John Cornyn (R-Texas) and Orrin Hatch (R-Utah) -- recently said that they will oppose Sonia Sotomayor"s confirmation to the Supreme Court, USA Today reports. The Judiciary Committee is scheduled to vote on Sotomayor"s nomination on Tuesday.In an opinion piece published Monday in USA Today, Sessions wrote that he questions Sotomayor"s "fidelity to the law," adding, "I don"t believe that Judge Sotomayor has the deep-rooted convictions necessary to resist the siren call of judicial activism. She has evoked its mantra too often." In reference to what Sessions said were discrepancies between her statements before the panel and her judicial record, he wrote, "Which Sotomayor will we get?" (Page, USA Today, 7/27).On Friday in floor remarks, Cornyn said, "While her record was generally in the mainstream, several of her decisions demonstrated the kind of liberal judicial activism that has steered the court in the wrong direction over the last few years." He added that "many of her public statements reflected a surprisingly radical view of the law." Cornyn also said that "those speeches contain very radical ideas on what the role of a judge is," noting that Sotomayor expressed a belief that there "is no objectivity in law; courts should change the law to make new policy; and ethnicity and gender can and even should impact a judge"s decision-making" (Bolton, The Hill, 7/24).Hatch, in a statement released Friday, said, "I reluctantly, and with a heavy heart, have found that I cannot support her nomination to the U.S. Supreme Court," adding, "Although Judge Sotomayor has a compelling life story and dedication to public service, her statements and record were too much at odds with the principles about the judiciary in which I deeply believe" (Stanton, Roll Call, 7/24).
generic viagra online
Top Food Scientist To Target Hidden Fish Allergens, Pork, With New Tests
The odds of contracting mad cow disease from banned or adulterated bovine protein lurking in raw or processed food for humans or meat-bone meal for livestock have declined over the past decade. So have the risks of purchasing fishy imposters billed as red snapper, ground beef that isn"t all cow, or spoiled meat that doesn"t look or smell bad ò€¦ yet.
News of the day
Meda: Onsolis Receives FDA Approval
The U.S. Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Onsolis uses a unique delivery system designed to give rapid and reliable delivery of fentanyl. The product consists of a small dissolvable disc for application of fentanyl to the buccal (inner lining of cheek) membranes. The product is unique and offers an important step to a better pain treatment of cancer patients.
Sexual Health

Phase III Data Showed Novartis Investigational Bronchodilator QAB149 Significantly Improved Lung Function In COPD Patients

The Novartis investigational bronchodilator QAB149 (indacaterol) met the primary efficacy endpoints of improved lung function compared to placebo at 12 weeks in three pivotal phase III studies in chronic obstructive pulmonary disease (COPD) patients. In secondary endpoints of these studies, QAB149 demonstrated clinically relevant lung function improvements within five minutes of the first dose, lasting for 24 hours in COPD patients. The QAB149 data, which were presented at the American Thoracic Society (ATS) 2009 International Conference in San Diego, are the first from the Phase III INVOLVE, INHANCE and INLIGHT-1 trials. These were three multinational, multi-center, randomized, double-blind, placebo-controlled studies in over 3,800 patients with moderate-to-severe COPD. "Current management of COPD focuses on the use of bronchodilators to optimize lung function," said Professor Stephen I. Rennard, Pulmonary and Critical Care Medicine, University of Nebraska Medical Center. "As presented at the ATS meeting, QAB149 is a long-acting beta-agonist bronchodilator given once daily that significantly improved both airflow and clinical outcomes. The ability to provide bronchodilation on a once-daily basis will be an important addition to the current therapeutic armamentarium in COPD." In the six-month INHANCE trial, QAB149 150÷µg and 300÷µg doses significantly improved lung function at 12 weeks compared to placebo. Improvements [measured by difference in trough forced expiratory volume in one second (FEV1 )] were observed after one day (110mL and 140mL), at the 12 week primary endpoint (both doses 180mL), and at 26 weeks (160mL and 180mL). Results were statistically significant (p Novartis Pharmaceuticals Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009